BAJAJ BROKING

Notification
No new Notification messages
Suraksha Diagnostic IPO is Open!
Apply for the Suraksha Diagnostic IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Q2 FY'24-25 Results of Top Companies
Reliance, TCS, HDFC Bank & more: Explore key financial highlights from India's top quarterly results.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Agilus Diagnostics Limited

-

Offer Period :

Agilus Diagnostics Limited, India's foremost healthcare provider, boasts the largest NABL-accredited laboratory network nationwide and international presence in Dubai and Nepal. Offering over 3600 tests, Read more...it integrates with Ayushman Bharat Digital Mission. With a total income of Rs. 13,711.02 million in FY 2023, Agilus focuses on a customer-centric omni-channel approach for seamless pathology and radiology services. Read less

Agilus Diagnostics Limited IPO Details

IPO Date - Minimum Investment ₹ / Lots
Listing Date Maximum Investment ₹ / Lots
Face Value ₹0 per share Total Issue Size ₹0 Crores
Price ₹0 to ₹0 per share Fresh Issue ₹0 Crores
Lot Size 1 Lots (0 Shares) Offer For Sale ₹ 0
Listing At Retail Discount ₹ 0
Employee Discount ₹0 per share    
IPO Date -
Listing Date
Face Value ₹0 per share
Price ₹0 to ₹0 per share
Lot Size 1 Lots (0 Shares)
Listing At
Employee Discount ₹0 per share
Minimum Investment ₹ / Lots
Maximum Investment ₹ / Lots
Total Issue Size ₹0 Crores
Fresh Issue ₹0 Crores
Offer For Sale
Retail Discount ₹ 0

Timeline

Important dates for allocation and IPO listing.

-

IPO Starts

-

IPO Ends

-

Allotment Date

-

Initiation of Refund

-

Credit of Shares to Demat Account

-

IPO Listing Date

Shareholder Pattern

  Pre-Issue Post-Issue
Promoter Group 0 0
Public Group 0 0

Agilus Diagnostics Limited IPO Reservation

QIB Shares Offered 0(0%)
NII (HNI) Shares Offered 0(0%)
Retail Shares Offered 0(0%)
Anchor Investor Shares Offered 0(0%)
Total Shares Offered 0
Total Shares With Anchor Investor 0

IPO Lot Size

ApplicationLotsSharesAmount
Retail (Min)---
Retail (Max)---
S-HNI (Min)---
S-HNI (Max)---

Agilus Diagnostics Limited IPO Registrar

KFin Techologies Ltd
Phone Number +91 40 6716 2222 / 18003094001
Email Id adl.ipo@kfintech.com
Our Website www.kfintech.com

Agilus Diagnostics Limited IPO Lead Manager

1. ICICI Securities Ltd

2. Axis Capital Ltd

3. Citigroup Global Markets India Pvt Ltd

Brief:

Explore IPOs


Explore comprehensive IPO details for every IPO. Access essential information such as listing price, listing date, issue price, lot size, issue size, minimum investment, and IPO timeline. Gain insights into the company's background, strengths, and potential risks. Track the subscription status and delve into the financials of the company, empowering yourself with crucial data for informed investment decisions. Stay ahead in the dynamic IPO market by staying informed on upcoming, ongoing, and past IPOs. 
 

Stay ahead in the ever-evolving IPO landscape with our comprehensive platform. We offer a holistic resource, ensuring you not only access essential details but also gain valuable insights into market trends. Navigate confidently, armed with intricate analyses, expert opinions, and real-time updates. Whether you're a seasoned investor or a novice, our user-friendly interface and extensive information empower you to make well-informed decisions. Experience the convenience of having a dedicated space where you can delve into the intricacies of IPOs, enabling a strategic and calculated approach to the dynamic stock market. 

Agilus Diagnostics Limited IPO Subscription LIVE Status

Category No. of shares offered No. of shares bid No. of subscribed

Strength of Agilus Diagnostics Limited

1. Experienced pan-India diagnostics service provider with a diversified presence and a growing network that is well positioned to capitalize on the expected growth in the Indian diagnostics industry.

2. Comprehensive test offerings providing one stop solution for diagnostic requirements.

3. Advanced information technology platform supported by integrated systems enabling customer-centric initiatives.

4. Well-balanced B2C and B2B revenue mix.

5. Quality network of accredited laboratories supported by R&D capabilities focused on genomics and nextgeneration diagnostics.

6. Strong parentage and experienced management team with significant industry experience.

Risks Involved

1. The company recently changed its brand which led to certain legal proceedings that are currently pending before the Delhi High Court. Any unfavorable outcome may have an adverse effect on its business, reputation, results of operations and financial condition.

2. Any failure to establish its new brand may adversely affect customer confidence in the company services or its inability to maintain and enhance its brand and reputation or any negative publicity and allegations, may have an adverse impact on its business, reputation, results of operations and financial condition.

3. Its trade mark applications in relation to its new brand, "Agilus Diagnostics" and "Agilus" are not yet registered, and some have been objected/ opposed by other parties. Any inability to obtain registration or otherwise protect its intellectual property rights, or any exposure to misappropriation and infringement claims by third parties, could have an adverse effect on its business, reputation, financial condition and results of operations.

4. Its Promoter, Fortis Healthcare Limited, is subject to certain regulatory and statutory proceedings, including an appeal pending before the Securities Appellate Tribunal and an ongoing investigation by the Serious Fraud Investigation Office for certain alleged improper transactions and non-compliance with applicable laws and regulations including the Companies Act. Any prolonged proceedings or adverse outcome of such proceedings in the future may have an adverse impact on its business and reputation.

5. There are outstanding litigation against the Company, Promoter, Directors, Group Companies and Subsidiaries. An adverse outcome in any of these proceedings may affect its reputation and standing and impact its future business and could have a material adverse effect on its business, results of operations, financial condition and cash flows.

6. The company is liable to protect its patients' personal information and any failure to protect such information, could materially and adversely affect its business, results of operations and financial condition.

7. The company is subject to various operational, reputational, medical and legal claims, regulatory actions or other liabilities arising from the provision of healthcare services and may be subject to liabilities arising from claims of malpractice and medical negligence which could adversely affect its business, results of operations and financial condition.

8. Its industry is highly regulated and requires it to obtain, renew and maintain statutory and regulatory permits, accreditations, licenses and comply with applicable safety, health, environmental, labor and other governmental regulations. Any regulatory changes or violations of such rules and regulations may adversely affect its business, results of operations and financial condition.

9. The company currently avail tax benefits and are entitled to certain incentives. Any change in these benefits and incentives applicable to it or a delay in disbursement of benefits under such schemes may affect its results of operations.

10. The company has entered into a master service agreement with its Promoter and certain other letters/ agreements with its Promoter and its affiliates in respect of providing certain laboratory management services to them and are dependent on them for a portion of its revenues. Any non-performance, non-renewal/ revision, substantial change in the agreed rates or termination of such agreements may adversely affect its business, results of operations and financial condition.

Why should you invest in

-

Financials

Particulars For the financial year ending (in ₹ million)
  2023 2022 2021
Total Assets 241.87 2279.96 1586.31
Total Liabilities 241.87 2279.96 1586.31
Total Expenses 121.29 1289.04 923.92
Total Revenue 
137.11 1618.35 1060.69
Profit After Tax 11.66 554.71 131.24
EBITDA 26.26 732.4 244.2
Adjusted EBITDA 0 0 0

Agilus Diagnostics Limited IPO Listing Details

Listing Date BSE Script Code NSE Symbol ISIN Final Issue Price
0 -
INE089F01014
₹0 per share

Listing Day Trading Information

Price Details BSE NSE
Final Issue Price ₹0 ₹0
Open ₹0 ₹0
Low ₹0 ₹0
High ₹0 ₹0
Low ₹0 ₹0

Frequently Asked Questions

What is Agilus Diagnostics Limited IPO?

Answer Field

Agilus Diagnostics Limited IPO is a [-] IPO of [-] equity shares of a face value of ₹[-] aggregating up to ₹[-] Crores. The issue is priced at ₹[-] to ₹[-] per share. The minimum order quantity is [-] Shares. The IPO opens on [-], and closes on [-]. KFin Techologies Ltd is the registrar for the IPO. The shares are proposed to be listed on [-].

When Agilus Diagnostics Limited IPO will open?

Answer Field

The Agilus Diagnostics Limited IPO opens on [-] and closes on [-].

What is the lot size of Agilus Diagnostics Limited?

Answer Field

Agilus Diagnostics Limited lot size is [-] shares, and the minimum amount required is ₹[-].

How to apply for Agilus Diagnostics Limited IPO?

Answer Field

You can apply in Agilus Diagnostics Limited IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. To apply for an IPO:

• Login to Bajaj Broking account App/Website & click on IPO

• Enter the number of lots and price at which you wish to apply.

• Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.

• You will receive a mandate notification to block funds in your UPI app.

• Approve the mandate request on your UPI and funds will be blocked.

When is Agilus Diagnostics Limited IPO allotment?

Answer Field

The finalization of Basis of Allotment for Agilus Diagnostics Limited IPO will be done on [-], and the allotted shares will be credited to your demat account by [-].

When is Agilus Diagnostics Limited IPO listing date?

Answer Field

The Agilus Diagnostics Limited listing date is [-].

Who is the registrar of Agilus Diagnostics Limited IPO?

Answer Field

The registrar of Agilus Diagnostics Limited IPO is KFin Techologies Ltd

Which company is the book-running lead manager of the IPO?

Answer Field

ICICI Securities Ltd,Axis Capital Ltd,Citigroup Global Markets India Pvt Ltd will be the book-running lead manager of this IPO.

What is the fresh issue of Agilus Diagnostics Limited IPO?

Answer Field

The fresh issue size is ₹[-] Crores equity shares.

What minimum lot size can retail subscribers subscribe to Agilus Diagnostics Limited?

Answer Field

Retail investors can subscribe to a minimum of one lot, [-] shares and ₹[-] amount.

How can I approve the UPI mandate request for Agilus Diagnostics Limited IPO?

Answer Field

To apply for Agilus Diagnostics Limited IPO, you need to log in to your demat account to complete the bidding process. Then, approve the payment mandate on your UPI app.

What is the price range of Agilus Diagnostics Limited?

Answer Field

The price of each Agilus Diagnostics Limited share will be ranging in between ₹[-] to ₹[-] per share.

What is the cut-off time for the UPI mandate for Agilus Diagnostics Limited IPO?

Answer Field

The cut-off time for the UPI mandate confirmation is 5:00 PM, [-].

No results found

Browse IPOs

upcoming-radio
  • IPO Name
  • Bidding Dates
  • Price range
  • IPO Size
  • Lorem Ipsum
current-radio
  • IPO Name
  • Bidding Dates
  • Price range
  • IPO Size
  • Lorem Ipsum
  • GANESH INFRAWORLD LIMITEDSME IPO

  • Bidding Dates

    29th Nov 2024 - 12th Dec 2024

  • Price Range

    ₹78.0 - 83.0

  • IPO Size

    ₹98,57,00,000

  • Apply Now
  • SURAKSHA DIAGNOSTIC LIMITEDMainboard IPO

  • Bidding Dates

    29th Nov 2024 - 12th Dec 2024

  • Price Range

    ₹420.0 - 441.0

  • IPO Size

    ₹8,46,25,00,000

  • Apply Now
closed-radio
  • IPO Name
  • Bidding Dates
  • Price range
  • IPO Size
  • Lorem Ipsum
  • SWIGGY LIMITEDMainboard IPO

  • Bidding Dates

    6th Nov 2024 - 11th Nov 2024

  • Price Range

    ₹371.0 - 390.0

  • IPO Size

    ₹1,13,27,43,00,000

  • Invest Now
performance-radio
  • IPO Name
  • ISSUE PRICE
  • LISTING DAY CLOSE
  • LISTING DAY(GAIN/LOSS)
  • Lorem Ipsum
  • ONYX BIOTEC LIMITEDSME IPO

  • Issue Price

    61.00

  • Listing Day Close

    56.75

  • Listing Day (Gain/Loss)

    -6.56

  • SWIGGY LIMITEDMainboard IPO

  • Issue Price

    390.00

  • Listing Day Close

    455.95

  • Listing Day (Gain/Loss)

    16.92

  • DANISH POWER LIMITEDSME IPO

  • Issue Price

    380.00

  • Listing Day Close

    598.50

  • Listing Day (Gain/Loss)

    57.63

We have something for everyone

Explore more Investment options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Related Articles

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs + Users

icon-with-text

4.8+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5000+ Cr MTF Book

icon-with-text